Study Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care

NCT ID: NCT00161668

Last Updated: 2007-03-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2001-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is designed to assess the safety of Mylotarg therapy in routine practice.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Myeloid Leukemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

DEFINED_POPULATION

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Mylotarg

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Treated by Mylotarg
* Provide ICF
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Medical Monitor

Role: STUDY_DIRECTOR

Wyeth is now a wholly owned subsidiary of Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Tucson, Arizona, United States

Site Status

Berkely, California, United States

Site Status

Burbank, California, United States

Site Status

Concord, California, United States

Site Status

Loma Linda, California, United States

Site Status

Los Angeles, California, United States

Site Status

San Francisco, California, United States

Site Status

Sylmar, California, United States

Site Status

Denver, Colorado, United States

Site Status

Boynton Beach, Florida, United States

Site Status

Plantation, Florida, United States

Site Status

Stuart, Florida, United States

Site Status

Tamarac, Florida, United States

Site Status

Chicago, Illinois, United States

Site Status

Chicago, Illinois, United States

Site Status

Chicago, Illinois, United States

Site Status

Chicago, Illinois, United States

Site Status

Indianapolis, Indiana, United States

Site Status

Iowa City, Iowa, United States

Site Status

Lexington, Kentucky, United States

Site Status

Louisville, Kentucky, United States

Site Status

Shrevport, Louisiana, United States

Site Status

Ann Arbor, Michigan, United States

Site Status

Grand Rapids, Michigan, United States

Site Status

Kalamazoo, Michigan, United States

Site Status

Kalamazoo, Michigan, United States

Site Status

Columbia, Missouri, United States

Site Status

St Louis, Missouri, United States

Site Status

Neptune City, New Jersey, United States

Site Status

Albuquerque, New Mexico, United States

Site Status

Buffalo, New York, United States

Site Status

New Hyde Park, New York, United States

Site Status

New York, New York, United States

Site Status

New York, New York, United States

Site Status

The Bronx, New York, United States

Site Status

Valhalla, New York, United States

Site Status

Durham, North Carolina, United States

Site Status

Winston-Salem, North Carolina, United States

Site Status

Bismarck, North Dakota, United States

Site Status

Akron, Ohio, United States

Site Status

Canton, Ohio, United States

Site Status

Cincinnati, Ohio, United States

Site Status

Cleveland, Ohio, United States

Site Status

Oklahoma City, Oklahoma, United States

Site Status

Portland, Oregon, United States

Site Status

Hershey, Pennsylvania, United States

Site Status

Philadelphia, Pennsylvania, United States

Site Status

Philadelphia, Pennsylvania, United States

Site Status

Pittsburgh, Pennsylvania, United States

Site Status

Memphis, Tennessee, United States

Site Status

Nashville, Tennessee, United States

Site Status

Nashville, Tennessee, United States

Site Status

Houston, Texas, United States

Site Status

Temple, Texas, United States

Site Status

Arlington, Virginia, United States

Site Status

Richmond, Virginia, United States

Site Status

Charleston, West Virginia, United States

Site Status

Morgantown, West Virginia, United States

Site Status

Appleton, Wisconsin, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

0903X-100847

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.